Phase II study of nab-paclitaxel as second-line chemotherapy prior fluoropyrimidine resistance for metastatic or recurrent gastric cancer considering dose reduction on early points

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 12 Oct 2017

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

12 Sep 2017 Results of exploratory analysis assessing correlation between (secreted protein acidic and rich in cysteine) SPARC expression and efficacy of nab-paclitaxel for advanced gastric cancer refractory to fluoropyrimidine, were presented at the 42nd European Society for Medical Oncology Congress.
21 Jan 2017 Status changed from recruiting to active, no longe recruiting, according to results presented at the 2017 Gastrointestinal Cancers Symposium.
21 Jan 2017 Results presented at the 2017 Gastrointestinal Cancers Symposium.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com